Scribe Raises $100M to Advance CRISPR as Means of Treating ALS

Scribe Raises $100M to Advance CRISPR as Means of Treating ALS

291688

Scribe Raises $100M to Advance CRISPR as Means of Treating ALS

Scribe Therapeutics has raised $100 million in funding to develop CRISPR-based gene editing tools and advance its pipeline of therapies for neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). “Scribe’s engineering-first philosophy has resulted in a uniquely flexible platform for imagining and creating a new era of CRISPR-based therapies to elevate the standard of care for thousands of patients,” Jennifer Doudna, PhD, co-founder of Scribe and co-inventor of the CRISPR technology, said in a press…

You must be logged in to read/download the full post.